Pharmaceutical News

RSS

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

Cryoablation shows potential as a treatment for low-risk breast cancer

Researchers at CentraState Medical Center have shown that cryoablation, also known as cryotherapy, could be an effective treatment for low-risk breast cancer.

28 Nov 2018

Antibiotics can effectively target and eliminate senescent cells

ANTIBIOTICS have emerged as potentially lifespan-enhancing drugs, according to the results of new research carried out in the UK.

28 Nov 2018

Freeze dried polio vaccine could help save lives in remote locations

Polio vaccine can successfully prevent the deadly paralyzing illness caused in children. The vaccine presently available is in liquid form and is also thermolabile.

28 Nov 2018

Toxicologists and pharmacologists meet at international conference in Adelaide

Experts will meet to discuss the latest discoveries in drugs and how best to use existing ones as effectively and safely as possible, at an international conference in Adelaide this week (27-30 November).

27 Nov 2018

Some clinical trials may promote use of ineffective and costly treatments, researchers say

A new paper published by McGill University researchers in JAMA Internal Medicine suggests that some clinical trials may promote the use of ineffective and costly treatments. That's the opposite of what clinical trials are aimed at, namely preventing ineffective and costly treatments from being taken up by physicians and patients.

27 Nov 2018

Researchers assess trends in efficacy of antibiotic prophylaxis regimens for surgical procedures

Antibiotic prophylaxis regimens are becoming less effective at preventing surgical site infections following colorectal surgery, researchers at the Center for Disease Dynamics, Economics & Policy and Princeton University determined through a systematic review of available literature.

27 Nov 2018

FDA grants accelerated approval to oncology drug for treatment of key genetic driver of cancer

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

27 Nov 2018

AI could reduce gadolinium dosage in MRI scans

A new study has shown that artificial intelligence could be used to dramatically reduce the amount of gadolinium used in MRI scans.

26 Nov 2018

$People with Alzheimer’s disease using strong opioids have increased risk of hip fracture$

People with Alzheimer’s disease using strong opioids have increased risk of hip fracture

People using strong painkillers, opioids, have twice the risk of hip fracture compared to non-opioid users, a new study from the University of Eastern Finland shows. The risk was highest in the first two months of opioid use.

26 Nov 2018

$Alternative drug linked with comparable risk of falls, major fractures as atypical antipsychotics in older dementia patients$

Alternative drug linked with comparable risk of falls, major fractures as atypical antipsychotics in older dementia patients

As physicians attempt to decrease antipsychotic use in seniors with dementia, they need to be aware that trazadone, frequently used as an alternative, is associated with a similar risk of falls and major fractures as atypical antipsychotics, according to new research in CMAJ.

26 Nov 2018

New analysis outlines potential cost of national Canadian pharmacare program

A new analysis in CMAJ http://www.cmaj.ca/lookup/doi/10.1503/cmaj.180897 outlines the potential government cost of a national Canadian pharmacare program and sets out approaches to shifting the funding for drugs in Canada to realize billions in savings.

26 Nov 2018

Prebiotic supplement may be effective alternative to reduce GI disturbances in autistic children

Diets free from gluten and casein are often recommended as a way to reduce gastrointestinal (GI) problems in children with autistic spectrum disorders.

22 Nov 2018

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

Anabolic steroids may increase risk of early death in men

Men who use androgenic anabolic steroids—such as testosterone—may face a higher risk of early death and of experiencing more hospital admissions, according to a new Journal of Internal Medicine study.

21 Nov 2018

Pharmacogenetic tests don't provide much information for prescribing antidepressants or antipsychotics

Pharmacogenetic tests are marketed as an aid to psychiatrists in selecting the antidepressant or antipsychotic medication that will work best in individual patients, based on their genetic makeup.

21 Nov 2018

Survey: Misconceptions about opioid use undermine pain control among Asian cancer patients

Misconceptions about the use of strong opioids showed to undermine optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy according to a cross-sectional survey conducted at the Sarawak General Hospital in Malaysia.

21 Nov 2018

Peanut allergies could soon have a drug treatment

Millions of individuals worldwide suffer from peanut allergies. Researchers are developing a new treatment for fighting this allergy. A clinical trial had been conducted and the results are in.

20 Nov 2018

Live probiotics can change existing gut flora and alter immune response

New research published in the International Journal of Pharmaceutics demonstrates that 'good' bacteria in the live probiotic SymproveTM can successfully reach and colonize the gut, where they go on to change the existing gut flora. They are also capable of modifying immune response.

20 Nov 2018

Cytocybernetics receives NIMH award to move into neuronal drug development

Cytocybernetics, a University at Buffalo spinoff, has received a $250,000 Small Business Innovation Research award from the National Institute of Mental Health (NIMH) to move into a new market: neuronal drug development.

20 Nov 2018

Pharmaceutical News

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Cryoablation shows potential as a treatment for low-risk breast cancer

Antibiotics can effectively target and eliminate senescent cells

Freeze dried polio vaccine could help save lives in remote locations

Toxicologists and pharmacologists meet at international conference in Adelaide

Some clinical trials may promote use of ineffective and costly treatments, researchers say

Researchers assess trends in efficacy of antibiotic prophylaxis regimens for surgical procedures

FDA grants accelerated approval to oncology drug for treatment of key genetic driver of cancer

AI could reduce gadolinium dosage in MRI scans

People with Alzheimer’s disease using strong opioids have increased risk of hip fracture

Alternative drug linked with comparable risk of falls, major fractures as atypical antipsychotics in older dementia patients

New analysis outlines potential cost of national Canadian pharmacare program

Prebiotic supplement may be effective alternative to reduce GI disturbances in autistic children

FDA approves new treatment for AML patients

Anabolic steroids may increase risk of early death in men

Pharmacogenetic tests don't provide much information for prescribing antidepressants or antipsychotics

Survey: Misconceptions about opioid use undermine pain control among Asian cancer patients

Peanut allergies could soon have a drug treatment

Live probiotics can change existing gut flora and alter immune response

Cytocybernetics receives NIMH award to move into neuronal drug development

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

Latest News